Who is sponsoring NCT00006291?

NCT00006291 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00006291 study?

NCT00006291 studies HIV Infections.

What drugs are being tested in NCT00006291?

Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin.

What is the status of NCT00006291?

NCT00006291 is currently COMPLETED.

Last reviewed 2021-10-28 · How we verify

A Phase II, Randomized, Partially Blinded Trial of Combinations of Potent Antiretroviral Therapy, HIV-Specific Immunizations, and Cycles of Interleukin-2 to Promote Efficient Control of Viral Replication

NCT00006291 Phase 2 COMPLETED

The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and effective in controlling viral load (level of HIV in the body). (This study has been changed to clarify drug name.) Anti-HIV drugs can help reduce a patient's viral load. However, HIV can still remain in CD4 cells (cells of the immune system that help fight infection). Combining an HIV vaccine, IL-2, or both with anti-HIV drugs may help reduce the number of HIV-infected cells.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 2
Status	COMPLETED
Enrolment	100
Completion	2005-10

Conditions

HIV Infections

Interventions

ALVAC(2)120(B,MN)GNP (vCP1452)
Aldesleukin

Countries

United States, Puerto Rico